Cleared Special

K171427 - Heli-FX Applier, Heli-FX Guide, Ancillary EndoAnchor Cassette (FDA 510(k) Clearance)

Class II Cardiovascular device cleared through the Special 510(k) pathway - typically does not require clinical trials.

K171427 · Medtronic Vascular, Inc. · Cardiovascular device
Jun 2017
Decision
29d
Days
Class 2
Risk

K171427 is an FDA 510(k) clearance for the Heli-FX Applier, Heli-FX Guide, Ancillary EndoAnchor Cassette. Classified as Endovascular Suturing System (product code OTD), Class II - Special Controls.

Submitted by Medtronic Vascular, Inc. (Santa Rosa, US). The FDA issued a Cleared decision on June 13, 2017 after a review of 29 days - a notably fast clearance cycle.

This device falls under the Cardiovascular FDA review panel, regulated under 21 CFR 870.3460 - the FDA cardiovascular device oversight framework. As a Special 510(k), this submission covers a manufacturer modification to an existing cleared device rather than a new device introduction.

Device pattern: Iterative device modification. Low regulatory complexity profile. This Special 510(k) clearance confirms that the manufacturer's modifications remained within the established regulatory envelope of the original cleared device.

Submission Details

510(k) Number K171427 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received May 15, 2017
Decision Date June 13, 2017
Days to Decision 29 days
Submission Type Special
Review Panel Cardiovascular (CV)
Summary Summary PDF
Regulatory Context
Review time vs. panel average
111d faster than avg
Panel avg: 140d · This submission: 29d
Pathway characteristics
Modification to existing cleared device.

Device Classification

Product Code OTD Endovascular Suturing System
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 870.3460
Definition Provides Fixation And Sealing Between And Endovascular Graft And The Native Artery.
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Cardiovascular devices follow this clearance model.